‘Syngoi Technologies’: Columbus VP creates a new company in Bizkaia for synthetic DNA production
Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an important bottleneck.
Syngoi has its own technology for the manufacture of its optimised synthetic DNA (orDNATM) which confers multiple advantages over traditional plasmid DNA. On the one hand, it does not require cell culture infrastructure and production times are reduced. On the other hand, it does not contain bacteria or antibiotic-resistant genes (relevant aspects for regulatory authorities). In addition, it offers advantages over other synthetic DNA, since it allows optimising the therapeutic response of the gene of interest, in accordance with the client’s use requirements, without any technological limitations.
Syngoi was created in 2021 and the works for the new facilities, located in the Bizkaia Science and Technology Park, begin in the last quarter of 2021 with the aim of being operational in the second quarter of 2022. It is expected that by the first quarter of 2023 the plant will be ready to produce in accordance with GMP quality (Good Manufacturing Standards) and will be a supplier to the leading companies in the growing market of advanced therapies: gene therapy and mRNA vaccines.
This infrastructure will involve an initial private investment of more than € 10M, creating dozens of high-level direct jobs. This reinforces Columbus’s commitment to the Basque Country and its positioning as one of the world’s leading production areas in advanced therapies. Javier Garcia, general partner from Columbus, adds: “We are delighted to announce the creation of Syngoi. It will be Columbus’s first investment in Bizkaia,and we think it will play a key role in the synthetic DNA production market.”
About Columbus Venture Partners
About Columbus Venture Partners. A Spanish venture capital investment management company with a singular focus on business opportunities emerging in the biotechnology and life sciences sector. Columbus VP supports the most innovative science that emerges in research centres and start-ups and stands by throughout its development until eventual marketing of new products and treatments that offer effective solutions to unmet medical needs.
Columbus VP has almost €235M under management in its funds Columbus INNVIERTE Life Science, Columbus Life Science Fund II and Columbus Life Science Fund III; andViralgen (CDMO gene therapy) is among its investees. Its team of professionals combines solid scientific, medical,and business knowledge with extensive experience in establishing and investing in biotechnology companies.
Related news
CIC biomaGUNE launches a company that will transform disease diagnosis by using nanosensors
Taldeki Biosolutions will be developing sensors for rapid, cost-effective, robust antibody detection, thus overcoming the stability and cost problems of current in vitro diagnostics
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
CIC nanoGUNE launches a new call: Industry Collaborative Research Positions
Programa honen helburua da ikertzaile profesionalak tokiko erakundeetan sar daitezen erraztea
Companies with greater gender equality perform better in terms of innovation and are more competitive
The study of the SPRI initiative "Women in Industry" shows that gender equality has an impact on the improvement of company results.
SPRI presents the results of the study on the impact of women on industrial competitiveness at the World Manufacturing Forum
The reports is the continuation of the work carried out by the SPRI Group and the Foreign Network office in Milan since 2020 as leader of the Women in Manufacturing expert group.
Europako fabrikazio-ikerketaren etorkizuna
Donostian, egunotan, MANUFUTURE Conference 2023 egiten ari da, hau da, fabrikazio-industriaren etorkizunari buruzko Europako konferentzia.
REBEL TICKETS resale platform, now available on your cell phone
Now you will be able to buy and sell your tickets in a simpler, more comfortable and accessible way.
Basque Open Industry will show Europe its industrial and technological ecosystem at the European SME Week (SME Week) from 13 to 17 November.
Talent, internationalisation, energy-environmental and technology-digital transitions. SME Week 2023. Exhibition and stands at the BEC: “Rebuild Ukraine”.
Aker Solutions selects TUBACEX as a delivery partner for umbilical tubes for key projects on the Norwegian Continental Shelf
An order intake for a sum of more than €70 million is one of the most significant deals in the umbilicals market. Solidifying TUBACEX’s technological position as a supplier of advanced industrial solutions for energy and mobility sectors.
Get to know the assets of the BDIH: 5-axis multi-process milling cell, capable of very high speed operations
The University of the Basque Country offers Basque companies, via the BDIH, the possibility to have at their disposal a 5-axis multi-process milling cell, capable of very high-speed operations.